8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Jan 29, 2026·SEC
ResMed Inc.(RMD)Earnings, Financials & Key Ratios
RMD•NYSE
19.8× P/E·Price updated Jun 19, 2026
AboutResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.Show more
- Revenue$5.15B+9.8%
- EBITDA$1.92B+25.1%
- Net Income$1.4B+37.2%
- EPS (Diluted)9.51+37.4%
- Gross Margin59.36%+4.7%
- EBITDA Margin37.33%+13.9%
- Operating Margin32.75%+16.3%
- Net Margin27.22%+24.9%
- ROE25.86%+13.9%
RMD Key Insights
ResMed Inc. (RMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 24.2%
- ✓Strong 5Y profit CAGR of 17.6%
- ✓Strong Piotroski F-Score: 8/9
- ✓FCF machine: 32.3% free cash flow margin
- ✓14 consecutive years of dividend growth
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak momentum: RS Rating 20 (bottom 20%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RMD Price & Volume
ResMed Inc. (RMD) stock price & volume — 10-year historical chart
Loading chart...
RMD Growth Metrics
ResMed Inc. (RMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.85%
5 Years11.72%
3 Years12.88%
TTM10.28%
Profit CAGR
10 Years14.78%
5 Years17.64%
3 Years21.58%
TTM15.71%
EPS CAGR
10 Years14.43%
5 Years17.37%
3 Years21.52%
TTM16.05%
Return on Capital
10 Years21.04%
5 Years23.41%
3 Years23.18%
Last Year25.7%
RMD Recent Earnings
ResMed Inc. (RMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$2.86+2.1%
$2.80
Rev
$1.4B+0.8%
$1.4B
Q1 2026
Jan 29, 2026Metric
Actual
Est
EPS
$2.81+2.6%
$2.74
Rev
$1.4B+1.6%
$1.4B
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$2.55+1.6%
$2.51
Rev
$1.3B+0.2%
$1.3B
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$2.55+0.0%
$2.55
Rev
$1.3B+0.0%
$1.3B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $2.86vs $2.80+2.1% | $1.4Bvs $1.4B+0.8% |
| Q1 2026 | Jan 29, 2026 | $2.81vs $2.74+2.6% | $1.4Bvs $1.4B+1.6% |
| Q4 2025 | Oct 30, 2025 | $2.55vs $2.51+1.6% | $1.3Bvs $1.3B+0.2% |
| Q3 2025 | Jul 31, 2025 | $2.55vs $2.55+0.0% | $1.3Bvs $1.3B+0.0% |
Based on last 12 quarters of dataView full earnings history →
RMD Peer Comparison
ResMed Inc. (RMD) competitors in Patient monitoring and respiratory care — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PHG | 25.5B | 26.78 | 25.02 | -1.04% | 5.49% | 8.96% | 0.74 | |
 ITGR | 3.13B | 90.96 | 31.47 | 7.57% | 7.67% | 8.23% | 0.80 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 INSP | 1.23B | 42.61 | 8.71 | 13.6% | 14.33% | 17.98% | 0.04 | |
 TNDM | 1.05B | 15.30 | -5.03 | 7.93% | -9.2% | -68.29% | 2.86 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 | |
 SYK | 117.88B | 307.80 | 36.64 | 11.16% | 12.92% | 15.04% | 0.66 | |
 BSX | 67.31B | 45.29 | 23.35 | 19.87% | 14.4% | 12.4% | 0.51 |
Compare RMD vs Peers
ResMed Inc. (RMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RMD Income Statement
ResMed Inc. (RMD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 2.07B | 2.34B | 2.61B | 2.96B | 3.2B | 3.58B | 4.22B | 4.69B | 5.15B | 5.54B |
Revenue Growth % | 12.4% | 13.23% | 11.38% | 13.44% | 8.11% | 11.93% | 18.02% | 10.95% | 9.84% | 10.28% |
Cost of Goods Sold | 864.99M | 978.03M | 1.07B | 1.24B | 1.36B | 1.55B | 1.87B | 2.03B | 2.09B | 2.12B |
COGS % of Revenue | 41.85% | 41.79% | 41.05% | 41.91% | 42.47% | 43.43% | 44.22% | 43.33% | 40.64% | - |
Gross Profit | 1.2B▲ 0% | 1.36B▲ 13.3% | 1.54B▲ 12.8% | 1.72B▲ 11.8% | 1.84B▲ 7.1% | 2.02B▲ 10.1% | 2.36B▲ 16.4% | 2.66B▲ 12.7% | 3.05B▲ 15.1% | 3.42B▲ 0% |
Gross Margin % | 58.15% | 58.21% | 58.95% | 58.09% | 57.53% | 56.57% | 55.78% | 56.67% | 59.36% | 61.69% |
Gross Profit Growth % | 12.68% | 13.35% | 12.8% | 11.79% | 7.06% | 10.07% | 16.37% | 12.72% | 15.05% | - |
Operating Expenses | 775.95M | 820.33M | 957.32M | 908.73M | 935.42M | 1.02B | 1.22B | 1.34B | 1.37B | 1.52B |
OpEx % of Revenue | 37.54% | 35.05% | 36.73% | 30.73% | 29.26% | 28.62% | 28.98% | 28.5% | 26.61% | - |
Selling, General & Admin | 553.97M | 600.37M | 645.01M | 676.69M | 670.39M | 739.37M | 874M | 917.14M | 991.02M | 1.08B |
SG&A % of Revenue | 26.8% | 25.65% | 24.75% | 22.88% | 20.97% | 20.66% | 20.7% | 19.57% | 19.26% | - |
Research & Development | 144.47M | 155.15M | 180.65M | 201.95M | 225.28M | 253.57M | 287.64M | 307.52M | 331.28M | 359M |
R&D % of Revenue | 6.99% | 6.63% | 6.93% | 6.83% | 7.05% | 7.09% | 6.81% | 6.56% | 6.44% | - |
Other Operating Expenses | 77.51M | 64.81M | 131.66M | 30.09M | 39.75M | 31.08M | 62.15M | 110.75M | 47.3M | 4M |
Operating Income | 425.8M▲ 0% | 541.83M▲ 27.3% | 579.26M▲ 6.9% | 809.66M▲ 39.8% | 903.68M▲ 11.6% | 1B▲ 10.7% | 1.13B▲ 13.2% | 1.32B▲ 16.6% | 1.69B▲ 27.7% | 1.9B▲ 0% |
Operating Margin % | 20.6% | 23.15% | 22.22% | 27.38% | 28.27% | 27.96% | 26.8% | 28.17% | 32.75% | 34.28% |
Operating Income Growth % | -0.74% | 27.25% | 6.91% | 39.77% | 11.61% | 10.69% | 13.15% | 16.61% | 27.69% | - |
EBITDA | 537.96M | 661.79M | 730.06M | 991.03M | 1.1B | 1.19B | 1.33B | 1.54B | 1.92B | 2.08B |
EBITDA Margin % | 26.03% | 28.28% | 28.01% | 33.51% | 34.26% | 33.37% | 31.46% | 32.79% | 37.33% | 37.61% |
EBITDA Growth % | 4.3% | 23.02% | 10.32% | 35.75% | 10.51% | 9.03% | 11.24% | 15.64% | 25.07% | 13.92% |
D&A (Non-Cash Add-back) | 112.16M | 119.96M | 150.79M | 181.37M | 191.52M | 193.84M | 196.52M | 216.21M | 235.81M | 184.32M |
EBIT | 456.73M | 560.26M | 555M | 809.06M | 912.35M | 982.79M | 1.16B | 1.31B | 1.68B | 1.92B |
Net Interest Income | -11.15M | -11.98M | -33.86M | -39.36M | -23.63M | -22.31M | -47.38M | -45.71M | -12.61M | -23.27M |
Interest Income | 17.09M | 16.38M | 2.3M | 1.02M | 362K | 0 | 0 | 0 | 0 | 5.76M |
Interest Expense | 28.24M | 28.36M | 36.16M | 40.38M | 23.99M | 22.31M | 47.38M | 45.71M | 12.61M | 29.03M |
Other Income/Expense | -7.05M | -20.52M | -60.42M | -76.57M | -20.02M | -39.8M | -30.21M | -55.09M | -7.8M | 4.82M |
Pretax Income | 418.74M▲ 0% | 521.31M▲ 24.5% | 518.85M▼ 0.5% | 733.09M▲ 41.3% | 883.66M▲ 20.5% | 960.48M▲ 8.7% | 1.1B▲ 14.7% | 1.26B▲ 14.8% | 1.68B▲ 32.6% | 1.9B▲ 0% |
Pretax Margin % | 20.26% | 22.28% | 19.91% | 24.79% | 27.64% | 26.84% | 26.09% | 27% | 32.6% | 34.37% |
Income Tax | 76.46M | 205.72M | 114.25M | 111.41M | 409.16M | 181.05M | 204.11M | 243.85M | 276.84M | 383.74M |
Effective Tax Rate % | 18.26% | 39.46% | 22.02% | 15.2% | 46.3% | 18.85% | 18.53% | 19.28% | 16.5% | 20.16% |
Net Income | 342.28M▲ 0% | 315.59M▼ 7.8% | 404.59M▲ 28.2% | 621.67M▲ 53.7% | 474.5M▼ 23.7% | 779.44M▲ 64.3% | 897.56M▲ 15.2% | 1.02B▲ 13.7% | 1.4B▲ 37.2% | 1.52B▲ 0% |
Net Margin % | 16.56% | 13.49% | 15.52% | 21.02% | 14.84% | 21.78% | 21.25% | 21.79% | 27.22% | 27.44% |
Net Income Growth % | -2.87% | -7.8% | 28.2% | 53.65% | -23.67% | 64.26% | 15.15% | 13.75% | 37.2% | 15.71% |
Net Income (Continuing) | 342.28M | 315.59M | 404.59M | 621.67M | 474.5M | 779.44M | 897.56M | 1.02B | 1.4B | 1.52B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 2.40▲ 0% | 2.19▼ 8.8% | 2.80▲ 27.9% | 4.27▲ 52.5% | 3.24▼ 24.1% | 5.30▲ 63.6% | 6.09▲ 14.9% | 6.92▲ 13.6% | 9.51▲ 37.4% | 10.33▲ 0% |
EPS Growth % | -3.61% | -8.75% | 27.85% | 52.5% | -24.12% | 63.58% | 14.91% | 13.63% | 37.43% | 16.05% |
EPS (Basic) | 2.42 | 2.21 | 2.83 | 4.31 | 3.27 | 5.34 | 6.12 | 6.94 | 9.55 | - |
Diluted Shares Outstanding | 142.45M | 143.99M | 144.48M | 145.65M | 146.45M | 147.04M | 147.46M | 147.55M | 147.34M | 147.04M |
Basic Shares Outstanding | 141.36M | 142.76M | 143.11M | 144.34M | 145.31M | 146.07M | 146.76M | 147.02M | 146.72M | 146.47M |
Dividend Payout Ratio | 54.44% | 63.21% | 52.33% | 36.21% | 47.78% | 31.48% | 28.78% | 27.65% | 22.19% | - |
RMD Balance Sheet
ResMed Inc. (RMD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.64B | 1.07B | 1.15B | 1.52B | 1.57B | 1.93B | 2.37B | 2.36B | 3.51B | 4.06B |
Cash & Short-Term Investments | 821.93M | 188.7M | 147.13M | 463.16M | 295.28M | 273.71M | 227.89M | 238.36M | 1.21B | 1.66B |
Cash Only | 821.93M | 188.7M | 147.13M | 463.16M | 295.28M | 273.71M | 227.89M | 238.36M | 1.21B | 1.66B |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 450.53M | 483.68M | 528.48M | 474.64M | 614.29M | 575.95M | 704.91M | 837.27M | 990.67M | 998.84M |
Days Sales Outstanding | 79.57 | 75.44 | 74 | 58.59 | 70.14 | 58.75 | 60.93 | 65.23 | 70.26 | 64.82 |
Inventory | 268.32M | 268.7M | 349.64M | 416.92M | 457.03M | 743.91M | 998.01M | 822.25M | 927.71M | 911.88M |
Days Inventory Outstanding | 113.22 | 100.28 | 119.27 | 122.8 | 122.87 | 174.75 | 195.08 | 147.84 | 161.91 | 159.48 |
Other Current Assets | 0 | 0 | 0 | 75.26M | 0 | 131.26M | 179.93M | 180.01M | 164.5M | 492.84M |
Total Non-Current Assets | 1.82B | 2B | 2.96B | 3.06B | 3.15B | 3.16B | 4.38B | 4.51B | 4.67B | 4.72B |
Property, Plant & Equipment | 394.24M | 386.55M | 387.46M | 535.68M | 592.07M | 630.5M | 665.81M | 699.15M | 718.29M | 728.57M |
Fixed Asset Turnover | 5.24x | 6.05x | 6.73x | 5.52x | 5.40x | 5.68x | 6.34x | 6.70x | 7.16x | 7.63x |
Goodwill | 1.06B | 1.07B | 1.86B | 1.89B | 1.93B | 1.94B | 2.77B | 2.84B | 3.05B | 3.47B |
Intangible Assets | 261.8M | 215.18M | 521.95M | 448.17M | 392.58M | 345.94M | 552.34M | 485.9M | 464.86M | 0 |
Long-Term Investments | 38.32M | 41.23M | 56.7M | 51.1M | 75.45M | 67.22M | 156.89M | 169.77M | 85.03M | 408.08M |
Other Non-Current Assets | 3.74M | 232.48M | 94.28M | 97.58M | 85.46M | 104.53M | 105.56M | 114.23M | 100.81M | 0 |
Total Assets | 3.47B▲ 0% | 3.06B▼ 11.7% | 4.11B▲ 34.1% | 4.59B▲ 11.7% | 4.73B▲ 3.1% | 5.1B▲ 7.8% | 6.75B▲ 32.5% | 6.87B▲ 1.8% | 8.17B▲ 18.9% | 8.78B▲ 0% |
Asset Turnover | 0.60x | 0.76x | 0.63x | 0.64x | 0.68x | 0.70x | 0.63x | 0.68x | 0.63x | 0.66x |
Asset Growth % | 6.43% | -11.66% | 34.07% | 11.68% | 3.07% | 7.78% | 32.49% | 1.79% | 18.95% | 69.14% |
Total Current Liabilities | 360.13M | 511.25M | 555.99M | 602.76M | 911.77M | 689.3M | 758.53M | 910.65M | 1.02B | 1.35B |
Accounts Payable | 92.76M | 92.72M | 115.72M | 135.79M | 138.01M | 159.25M | 150.76M | 237.73M | 278.16M | 273.3M |
Days Payables Outstanding | 39.14 | 34.6 | 39.48 | 39.99 | 37.1 | 37.41 | 29.47 | 42.74 | 48.55 | 45.97 |
Short-Term Debt | 0 | 11.47M | 11.99M | 11.99M | 12M | 9.92M | 9.9M | 9.9M | 9.9M | 289.16M |
Deferred Revenue (Current) | 51.92M | 60.83M | 88.67M | 98.62M | 109.61M | 108.67M | 138.07M | 152.55M | 166.03M | 689.13M |
Other Current Liabilities | 460K | 2.37M | 244K | 0 | 0 | 1.95M | 9.56M | 4.65M | 2.69M | 609.47M |
Current Ratio | 4.57x | 2.08x | 2.06x | 2.53x | 1.73x | 2.80x | 3.12x | 2.59x | 3.44x | 3.01x |
Quick Ratio | 3.82x | 1.56x | 1.43x | 1.84x | 1.23x | 1.72x | 1.81x | 1.69x | 2.53x | 2.33x |
Cash Conversion Cycle | 153.65 | 141.11 | 153.8 | 141.39 | 155.9 | 196.09 | 226.54 | 170.33 | 183.63 | 178.33 |
Total Non-Current Liabilities | 1.15B | 493.69M | 1.48B | 1.49B | 930.68M | 1.05B | 1.86B | 1.1B | 1.19B | 941.16M |
Long-Term Debt | 1.08B | 269.99M | 1.26B | 1.16B | 643.35M | 765.33M | 1.43B | 697.31M | 658.39M | 554.01M |
Capital Lease Obligations | 0 | 0 | 0 | 101.88M | 114.78M | 120.45M | 116.85M | 141.44M | 153.01M | 454.96M |
Deferred Tax Liabilities | 13.82M | 13.08M | 11.38M | 13.01M | 11.32M | 9.71M | 90.65M | 79.34M | 77.68M | 311.18M |
Other Non-Current Liabilities | 2.43M | 139.03M | 128.11M | 121.26M | 69.73M | 54.86M | 105.35M | 42.26M | 141.52M | 309.23M |
Total Liabilities | 1.51B | 1B | 2.04B | 2.09B | 1.84B | 1.74B | 2.62B | 2.01B | 2.21B | 2.29B |
Total Debt | 1.08B | 281.45M | 1.27B | 1.3B | 793.72M | 917.55M | 1.58B | 873.93M | 851.81M | 843.17M |
Net Debt | 256.68M | 92.75M | 1.12B | 836.11M | 498.44M | 643.84M | 1.35B | 635.57M | -357.64M | -817.34M |
Debt / Equity | 0.55x | 0.14x | 0.61x | 0.52x | 0.28x | 0.27x | 0.38x | 0.18x | 0.14x | 0.13x |
Debt / EBITDA | 2.01x | 0.43x | 1.74x | 1.31x | 0.72x | 0.77x | 1.19x | 0.57x | 0.44x | 0.40x |
Net Debt / EBITDA | 0.48x | 0.14x | 1.54x | 0.84x | 0.46x | 0.54x | 1.02x | 0.41x | -0.19x | -0.39x |
Interest Coverage | 16.18x | 19.76x | 15.35x | 20.04x | 38.03x | 44.05x | 24.53x | 28.67x | 133.05x | 66.06x |
Total Equity | 1.96B▲ 0% | 2.06B▲ 5.0% | 2.07B▲ 0.6% | 2.5B▲ 20.5% | 2.89B▲ 15.6% | 3.36B▲ 16.5% | 4.13B▲ 22.9% | 4.86B▲ 17.8% | 5.97B▲ 22.7% | 6.49B▲ 0% |
Equity Growth % | 15.66% | 5.04% | 0.64% | 20.5% | 15.56% | 16.46% | 22.89% | 17.78% | 22.69% | 77.9% |
Book Value per Share | 13.76 | 14.30 | 14.34 | 17.14 | 19.70 | 22.86 | 28.01 | 32.97 | 40.50 | 44.15 |
Total Shareholders' Equity | 1.96B | 2.06B | 2.07B | 2.5B | 2.89B | 3.36B | 4.13B | 4.86B | 5.97B | 6.49B |
Common Stock | 569K | 571K | 575K | 580K | 583K | 586K | 588K | 588K | 761K | 763K |
Retained Earnings | 2.32B | 2.43B | 2.44B | 2.83B | 3.08B | 3.61B | 4.25B | 4.99B | 6.08B | 6.96B |
Treasury Stock | -1.55B | -1.6B | -1.62B | -1.62B | -1.62B | -1.62B | -1.62B | -1.77B | -2.07B | -2.58B |
Accumulated OCI | -189.06M | -224.33M | -253.01M | -283.98M | -193.49M | -312.75M | -272.53M | -251.53M | -74.7M | -24.91M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RMD Cash Flow Statement
ResMed Inc. (RMD) cash flow — operating, investing & free cash flow history
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 414.05M | 505.03M | 459.05M | 802.25M | 736.72M | 351.15M | 693.3M | 1.4B | 1.75B | 1.89B |
Operating CF Margin % | 20.03% | 21.58% | 17.61% | 27.13% | 23.05% | 9.81% | 16.42% | 29.91% | 34.04% | - |
Operating CF Growth % | -24.43% | 21.97% | -9.1% | 74.76% | -8.17% | -52.34% | 97.44% | 102.11% | 25% | 68.74% |
Net Income | 342.28M | 315.59M | 404.59M | 621.67M | 474.5M | 779.44M | 897.56M | 1.02B | 1.4B | 1.52B |
Depreciation & Amortization | 112.16M | 119.96M | 150.79M | 181.37M | 191.52M | 193.84M | 197.56M | 216.21M | 235.81M | 263.32M |
Stock-Based Compensation | 45.92M | 48.41M | 52.07M | 57.56M | 63.93M | 65.26M | 71.14M | 80.18M | 91.66M | 101.64M |
Deferred Taxes | 1.96M | 11.59M | 28.93M | 39.58M | -3.31M | 0 | 216K | 0 | 0 | 0 |
Other Non-Cash Items | 1.62M | 411K | -286K | -7K | 8.67M | 20.69M | -11.05M | 39.13M | 6.66M | -4.23M |
Working Capital Changes | -89.88M | 9.06M | -177.05M | -97.92M | 1.41M | -708.08M | -462.13M | 44.78M | 16.74M | 9.67M |
Change in Receivables | -63.6M | -32.36M | -18.01M | 54.38M | -129.19M | 19.35M | -106.51M | -134.28M | -76.68M | -64.78M |
Change in Inventory | -41.6M | 1.49M | -84.19M | -69.88M | -21.95M | -311.68M | -248.83M | 172.2M | -80.17M | -8.19M |
Change in Payables | 34.58M | 200.65M | -27.28M | -23.42M | 210.71M | -247.63M | 31.34M | 0 | 90.96M | 0 |
Cash from Investing | -81.89M | -101.82M | -1.08B | -179.86M | -158.46M | -229.92M | -1.16B | -269.78M | -200.04M | -295.26M |
Capital Expenditures | -71.48M | -71.46M | -77.34M | -105.94M | -116.83M | -156.04M | -134M | -99.46M | -89.86M | -138.94M |
CapEx % of Revenue | 3.46% | 3.05% | 2.97% | 3.58% | 3.65% | 4.36% | 3.17% | 2.12% | 1.75% | 2.51% |
Acquisitions | -7.27M | -902K | -951.38M | -27.91M | -39.07M | -42.78M | -1.01B | -133.46M | -139.25M | -163.98M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 3.32M | 8.97M | -8.63M | -10.61M | 19.22M | -17.18M | 15.2M | -15.4M | 35.48M | 35.96M |
Cash from Financing | -262.87M | -1.03B | 580.64M | -317.29M | -764.63M | -128.36M | 422.87M | -1.12B | -606.25M | -907.75M |
Debt Issued (Net) | -95M | -796.24M | 807.49M | -94.01M | -522M | 122M | 665M | -730M | -40M | -10M |
Equity Issued (Net) | 38.32M | -69.19M | 13.88M | 48.18M | 37.79M | 47.38M | 49.14M | -96.92M | -225.59M | -524.7M |
Dividends Paid | -186.35M | -199.5M | -211.71M | -225.09M | -226.71M | -245.34M | -258.28M | -282.32M | -310.88M | -340.16M |
Share Repurchases | 0 | -53.8M | -22.84M | 0 | 0 | 0 | 0 | -150.01M | -300.02M | -600.04M |
Other Financing | -19.84M | 38.23M | -29.01M | -46.36M | -53.71M | -52.41M | -32.99M | -10.05M | -29.79M | -32.89M |
Net Change in Cash | 90.5M▲ 0% | -633.23M▼ 799.7% | -41.57M▲ 93.4% | 316.03M▲ 860.2% | -167.88M▼ 153.1% | -21.57M▲ 87.2% | -45.82M▼ 112.4% | 10.47M▲ 122.9% | 971.09M▲ 9175.0% | 727.8M▲ 0% |
Free Cash Flow | 342.58M▲ 0% | 433.57M▲ 26.6% | 381.71M▼ 12.0% | 696.32M▲ 82.4% | 619.89M▼ 11.0% | 195.11M▼ 68.5% | 559.3M▲ 186.7% | 1.29B▲ 130.0% | 1.66B▲ 29.2% | 1.75B▲ 0% |
FCF Margin % | 16.58% | 18.53% | 14.64% | 23.55% | 19.39% | 5.45% | 13.24% | 27.46% | 32.29% | 31.68% |
FCF Growth % | -28.65% | 26.56% | -11.96% | 82.42% | -10.98% | -68.53% | 186.66% | 130% | 29.18% | 12.14% |
FCF per Share | 2.40 | 3.01 | 2.64 | 4.78 | 4.23 | 1.33 | 3.79 | 8.72 | 11.28 | 11.93 |
FCF Conversion (FCF/Net Income) | 1.21x | 1.60x | 1.13x | 1.29x | 1.55x | 0.45x | 0.77x | 1.37x | 1.25x | 1.15x |
Interest Paid | 28.24M | 28.36M | 36.16M | 40.38M | 23.99M | 22.31M | 47.38M | 45.71M | 28.41M | 13.76M |
Taxes Paid | 92.9M | 170.65M | 242.86M | 180.36M | 221.36M | 478.12M | 216.87M | 278.4M | 214.01M | -135.96M |
RMD Key Ratios
ResMed Inc. (RMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 18.73% | 15.7% | 19.59% | 27.21% | 17.63% | 24.96% | 23.96% | 22.7% | 25.86% | 24.41% |
Return on Invested Capital (ROIC) | 14.67% | 18.6% | 16.25% | 18.6% | 20.18% | 20.31% | 17.9% | 18.03% | 22.75% | 25.01% |
Gross Margin | 58.15% | 58.21% | 58.95% | 58.09% | 57.53% | 56.57% | 55.78% | 56.67% | 59.36% | 61.69% |
Net Margin | 16.56% | 13.49% | 15.52% | 21.02% | 14.84% | 21.78% | 21.25% | 21.79% | 27.22% | 27.44% |
Debt / Equity | 0.55x | 0.14x | 0.61x | 0.52x | 0.28x | 0.27x | 0.38x | 0.18x | 0.14x | 0.13x |
Interest Coverage | 16.18x | 19.76x | 15.35x | 20.04x | 38.03x | 44.05x | 24.53x | 28.67x | 133.05x | 66.06x |
FCF Conversion | 1.21x | 1.60x | 1.13x | 1.29x | 1.55x | 0.45x | 0.77x | 1.37x | 1.25x | 1.15x |
Revenue Growth | 12.4% | 13.23% | 11.38% | 13.44% | 8.11% | 11.93% | 18.02% | 10.95% | 9.84% | 10.28% |
Related:RMD Dividend History·RMD Revenue History·RMD Price History·RMD P/E History·RMD Financial Ratios·RMD Institutional Holders
RMD SEC Filings & Documents
ResMed Inc. (RMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
RMD Frequently Asked Questions
ResMed Inc. (RMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ResMed Inc. (RMD) reported $5.54B in revenue for fiscal year 2025. This represents a 15905% increase from $34.6M in 1996.
ResMed Inc. (RMD) grew revenue by 9.8% over the past year. This is steady growth.
Yes, ResMed Inc. (RMD) is profitable, generating $1.52B in net income for fiscal year 2025 (27.2% net margin).
Dividend & Returns
Yes, ResMed Inc. (RMD) pays a dividend with a yield of 1.12%. This makes it attractive for income-focused investors.
ResMed Inc. (RMD) has a return on equity (ROE) of 25.9%. This is excellent, indicating efficient use of shareholder capital.
ResMed Inc. (RMD) generated $1.75B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.